Dr. Tim Huang's lab have been
conducting epigenetic/genetic analyses of cancer for the last twenty years and
have pioneered the development of high-throughput microarray and
next-generation sequencing technologies for integrative analysis of cancer
genomes. These omics approaches are used in combination with statistical
and bioinformatic tools to develop biological models of tumor
More recently, our research team has developed novel
technologies to characterize single cancer cells and to address intra-tumor
heterogeneity in prostate cancer patients. These novel technologies
include isolation of single prostate tumor cells from blood and urine samples,
single-cell expression profiling with microfluidic devices, and single-cell
topographical analysis using atomic force microscopy.
technologies will now be used for early detection and for identifying prostate
cancer patients who are at risk of advanced development.
Hsu PY, Hsu HK, Lan X, Juan L, Yan PS, Labanowska J, Heerema N, Hsiao
TH, Chiu YC, Chen Y, Liu Y, Li L, Li R, Thompson IM, Nephew KP, Sharp
ZD, Kirma NB, Jin VX, Huang TH. Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell. 2013 Aug 12;24(2):197-212.
Hsu YT, Gu F, Huang YW, Liu J, Ruan J, Huang RL, Wang CM, Chen CL,
Jadhav RR, Lai HC, Mutch DG, Goodfellow PJ, Thompson IM, Kirma NB, Huang
TH. Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clin Cancer Res. 2013 Nov 15;19(22):6272-85.
Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach RJ, Chang
TC, Weitman SD, Kumar AP, Sun L, Gaczynska ME, Thompson IM, Huang TH. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate. 2013 Jun;73(8):813-26.